City

Linkoping (1)

Lund (1)

Condition

Diabetic Foot Ulcer (2)

Diabetic Foot Ulcer Mixed (2)

Diabetic Foot (1)

Diabetic Foot Infection (1)

Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot) (1)

Wound Heal (1)

Wound Healing Delayed (1)

Wound Healing Disorder (1)

Wound Healing Disturbance of (1)

Overall Status

Recruiting (1)

Withdrawn (1)

Sign in for free

Phase

early phase 1 (1)

phase 2 (1)

Sponsor

Ilya Pharma (1)

Johns Hopkins University (1)

Collaborator

European Commission (1)

Intervention

ilp100-topical (emilimogene sigulactibac) 1x10^9 cfu/cm^2 (1)

ilp100-topical (emilimogene sigulactibac) 5x10^7 cfu/cm^2 (1)

neox® cord 1k® (1)

placebo (1)

Study Documents

Intervention Type

biological (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

diabetic foot ulcer mixed

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Wound Heal, Wound Healing Disturbance of, Wound Healing Disorder Trial in Linköping, Lund (ILP100-Topical (emilimogene

Recruiting

Wound Heal
+5 more

ILP100-Topical (emilimogene sigulactibac) 5x10^7 CFU/cm^2
+2 more

Linköping, Sweden
+1 more

Oct 31, 2022

Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot), Diabetic Foot Ulcer, Diabetic Foot Trial

Withdrawn

Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
+4 more

NEOX® CORD 1K®

(no location specified)

Feb 25, 2019